Меню
Набор скоро начнётся NCT07216040

Harnessing Optimism and Perseverance in the Face of Long COVID-Español

Без фазы С лечением Post-Acute COVID-19 Syndrome

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: HOPE-LC~Espanol.
Кому может быть актуально
Состояния в реестре: Post-Acute COVID-19 Syndrome. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
США
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Harnessing Optimism and Perseverance in the Face of Long COVID~Español (HOPE-LC~Español)

Обзор

The Harnessing Optimism and Perseverance in the Face of Long COVID (HOPE-LC) program, created by Drs. Eric Watson and Amelia Hicks, is a group therapy model designed to foster resilience, adjustment, and coping skills for those living with chronic Long COVID. HOPE-LC\~Español provides a culturally and linguistically adapted version for Spanish-speaking individuals in Queens, developed with input from Spanish-speaking clinicians, Long COVID experts, and people with lived experience. Partnering with H+H/Elmhurst and H+H/Queens, the project aims to recruit 25 participants and evaluate program feasibility and preliminary efficacy.

Подробное описание

The Harnessing Optimism and Perseverance in the Face of Long COVID (HOPE-LC) program, developed by Drs. Eric Watson (PI) and Amelia Hicks (co-I), is a 12-week online group therapy program tailored specifically to living with Long COVID as a chronic condition. HOPE-LC provides community and hope; fostering resilience, adjustment, and critical coping strategies in the face of this debilitating chronic condition. Since its inception in 2024, the HOPE-LC groups have engaged 20 patients, emphasizing the need for chronic Long COVID therapeutic interventions.

Through HOPE-LC-Espanol the researchers will translate and adapt the HOPE-LC program into Spanish and expand HOPE-LC's reach to underserved Spanish-speaking communities in Queens and NYC. The aims are: (1) To translate and culturally adapt the HOPE-LC program for Spanish-speaking patients in collaboration with the Advisory Board of Spanish-speaking clinicians, Long COVID experts, and individuals with Long COVID lived experience; (2) In collaboration with the partners at H+H/Elmhurst and H+H/Queens, to conduct targeted recruitment to ensure the researchers are engaging specifically with local Hispanic/Latinx communities in Queens; and (3) To complete the HOPE-LC\~Español program for 25 Spanish-speaking individuals experiencing Long COVID within the local Queens community. The researchers will evaluate program feasibility and treatment success to inform future scalability and sustainability as a clinical program.

Вмешательства

  • Поведенческое HOPE-LC~Espanol
    12-week online group therapy program grounded in principles of Acceptance and Commitment Therapy and tailored specifically to living with Long COVID as a chronic condition. HOPE-LC provides community and hope; fostering resilience, adjustment, and critical coping strategies in the face of this debilitating chronic condition.

Первичные конечные точки

  • Recruitment rate [Срок оценки: Throughout the study period, 12 weeks]
  • Retention rate [Срок оценки: Throughout the study period, 12 weeks]
  • Number of sessions participants attended [Срок оценки: Throughout the study period, 12 weeks]
  • Number of completed surveys [Срок оценки: Throughout the study period, 12 weeks]
  • Patient Satisfaction [Срок оценки: Post-treatment (Week 12)]
Вторичные конечные точки (6)
  • DePaul Symptom Questionnaire [Срок оценки: Baseline; 6 weeks, 12 weeks]
  • Brief Illness Perception Questionnaire (BIPQ) [Срок оценки: Baseline; 6 weeks, 12 weeks]
  • Valued Based Living Questionnaire (VLQ) [Срок оценки: Baseline; 6 weeks, 12 weeks]
  • Modified COVID-19 Yorkshire Rehabilitation Scale (C19-YRSm) [Срок оценки: Baseline; 6 weeks, 12 weeks]
  • Patient Health Questionnaire-8 Item (PHQ-8) [Срок оценки: Baseline; 6 weeks, 12 weeks]
  • Generalized Anxiety Disorder-7 Item (GAD-7) [Срок оценки: Baseline; 6 weeks, 12 weeks]

Критерии участия

Критерии включения

  • Age 18 years or older.
  • Speaks and understands Spanish at a level that allows active participation in group-based study procedures.
  • Self-reported history of Long COVID/post-COVID condition of any severity or duration, including ongoing emotional or cognitive symptoms affecting daily functioning or a medical professional has diagnosed you with a Long COVID/post-COVID condition of any severity or duration, including ongoing emotional or cognitive symptoms.
  • Ability to participate in group sessions either in-person or via telehealth (Zoom).
  • Willingness and capacity to provide informed consent.

Критерии исключения

  • Presence of severe psychiatric conditions that would preclude participation in group therapy (e.g., active psychosis, suicidal intent requiring immediate intervention).
  • Inability to communicate in Spanish sufficiently to engage meaningfully in group sessions.
  • Cognitive or physical impairments prevent participation in group sessions or completion of surveys, without available accommodations.
  • Concurrent participation in another conflicting interventional trial targeting Long COVID symptoms.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Не применимо
Модель
Одна группа
Маскирование
Открытое
Основная цель
Лечение

Центры проведения

США · 1 центр
  • Brain Injury Research Center — New York

Идентификаторы

NCT: NCT07216040 · STUDY-25-01010

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗